Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119822
Chunk: 167

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 167
---
 which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and
investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock.

The precise
amount and timing of the application of these proceeds will depend upon a number of factors, such as the costs and timing of commercial and development activities, including, for example, conducting preclinical studies and clinical trials, our
funding requirements and the availability and costs of other funds. Pending application of the proceeds as described above, we intend to temporarily invest the proceeds in interest-bearing instruments.

104

DETERMINATION OF OFFERING PRICE

We cannot currently determine the price or prices at which shares of our Common Stock may be sold by the Selling Securityholder under this
prospectus.

105

MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY

Market Information

Our Common Stock and
Public Warrants are currently listed on Nasdaq under the symbols “SCLX” and “SCLXW,” respectively. Prior to the consummation of the Business Combination, Vickers’s Ordinary Shares, units and warrants were each listed on
Nasdaq under the symbols “VCKA,” “VCKAU” and “VCKAW,” respectively. At the Effective Time, without any action on the part of the holder, each Unit then outstanding separated automatically into its component securities,
comprised of one share of Common Stock and one-half of one warrant to purchase one share of Common Stock. As of March 31, 2025 and taking into account the effect of the Reverse Stock Split, there were 244
holders of record of our Common Stock and one holder of record of our Public Warrants, which amount does not include participants of The Depository Trust Company or beneficial owners holding shares through nominee names.

Dividend Policy

Except as set forth
below, we have never declared or paid any dividend on shares of our Common Stock. We anticipate that we will retain all of our future earnings, if any, to fund the development and growth of our business. Any future determination to pay dividends on
our capital stock will be at the discretion of our Board. It is the present intention of our Board to retain all earnings, if any, for use in our business operations and, accordingly, our Board does not anticipate declaring any dividend in the
foreseeable future, except as disclosed in the section titled “Use of Proceeds”.